Molecule News and Research

RSS

AMG 386 demonstrates antitumor activity in Phase 2 trial involving patients with recurrent ovarian cancer

Amgen today announced that AMG 386, combined with paclitaxel, demonstrated antitumor activity in a randomized Phase 2 trial involving 161 patients with recurrent ovarian cancer. The results are being presented for the first time in an oral presentation at the 2010 American Society of Clinical Oncology Annual Meeting.

7 Jun 2010

Exelixis reports updated interim data from trials of XL765 small molecule inhibitor of PI3K and mTOR

Exelixis, Inc. today reported updated interim data from three ongoing trials of XL765 (SAR245409), an orally available small molecule inhibitor of phosphoinositide-3-kinase (PI3K) and mTOR. Activation of the PI3K pathway is a frequent event in human tumors, promoting cell proliferation, survival, and resistance to chemotherapy and radiotherapy.

7 Jun 2010

Tranzyme Pharma receives BioQuébec's 2010 Genesis Award for "Innovation"

Tranzyme Pharma, a clinical-stage biopharmaceutical company, announced today that the Company has been awarded BioQuébec's 2010 Genesis Award for "Innovation", having demonstrated strong and proven innovation in the field of life sciences.

7 Jun 2010

Ipilimumab extends survival of metastatic melanoma patients: Study

A therapy that multiplies the effect of a natural disease-fighting antibody has extended the lives of patients with metastatic melanoma in a large, international clinical trial. The study's researchers will report their findings simultaneously at the American Society of Clinical Oncology (ASCO) annual meeting in Chicago and in the New England Journal of Medicine.

7 Jun 2010

Plexxikon announces Phase 1 extension study results of PLX4032 in metastatic colorectal cancer

Plexxikon announced today the results of a Phase 1 extension study in metastatic colorectal cancer that showed clinical activity of PLX4032 as a single agent in this hard-to-treat patient population. PLX4032 is a novel, oral small molecule targeting an oncogenic BRAF mutation found in over 50 percent of melanomas, about 10 percent of colorectal cancers and eight percent of all solid tumors.

7 Jun 2010

Positive results from Phase 3 trial of ipilimumab in patients with metastatic melanoma

Bristol-Myers Squibb Company today announced positive results from a Phase 3 randomized, double blind study of ipilimumab which demonstrated that overall survival was significantly extended in patients with previously-treated metastatic melanoma who received ipilimumab.

7 Jun 2010

Endocyte presents interim results from phase II trial of EC145 plus Doxil for platinum-resistant ovarian cancer

Endocyte Inc., a company developing targeted small-molecule drug conjugates, will present results of an interim analysis from a randomized phase II clinical trial in women with platinum-resistant ovarian cancer on Sunday (June 6) during the 46th annual meeting of the American Society of Clinical Oncology in Chicago.

7 Jun 2010

Celldex reports interim positive results from rindopepimut Phase 2b study for GBM at ASCO

Celldex Therapeutics, Inc. today announced that interim results from a Phase 2b study evaluating rindopepimut (formerly PF-04948568 or CDX-110) in newly-diagnosed glioblastoma multiforme (GBM) patients were presented at the 46th Annual Meeting of the American Society of Clinical Oncology (ASCO).

7 Jun 2010

New clinical research findings on oncology to be highlighted at ASCO 2010

Researchers from University Hospitals Case Medical Center's Ireland Cancer Center will present new clinical research findings at the 46th Annual Meeting of The American Society of Clinical Oncology June 4-8 in Chicago.

5 Jun 2010

Vandetanib in combination with chemotherapy improves progression-free survival in patients with lung cancer

When combined with standard chemotherapy, an international Phase III trial has shown that the oral targeted therapy vandetanib improves progression-free survival for patients with advanced non-small cell lung cancer, according to research from The University of Texas MD Anderson Cancer Center.

5 Jun 2010

Ascenta Therapeutics, sanofi-aventis sign global licensing agreement for cancer drug candidates

Ascenta Therapeutics announced today the signing of a global collaboration and licensing agreement with sanofi-aventis covering several early-stage agents being investigated for their potential to restore tumor cell apoptosis (programmed cell death). These orally-active, small-molecule drug candidates inhibit the interaction between HDM2 (Human Double Minute 2) and p53, removing a block to normal p53 tumor suppressor function and potentially enhancing cancer control and treatment.

4 Jun 2010

Ascalon International signs license agreement with CerRx

Ascalon International Inc., a newly established oncology drug developer, today announced an agreement for an exclusive option to license CerRx Inc's intravenous fenretinide product.

4 Jun 2010

Preclinical data of dual TLR7 and TLR8 agonist in cancer published

Idera Pharmaceuticals, Inc. today announced the publication of data from studies of a dual agonist of Toll-like Receptor 7 and TLR8 in preclinical models of cancer. The Company created this first-in-class RNA-based dual agonist of TLR7 and TLR8 through its chemistry-based approach to identifying novel TLR-targeted drug candidates.

4 Jun 2010

Researchers develop biosensors to monitor concentration of c-di-GMP within single living bacteria cells

Some species of bacteria perform an amazing reproductive feat. When the single-celled organism splits in two, the daughter cell - the swarmer - inherits a propeller to swim freely. The mother cell builds a stalk to cling to surfaces.

4 Jun 2010

Boehringer Ingelheim to present new data on BIBW 2992 for NSCLC and head-and-neck cancer at ASCO 2010

Boehringer Ingelheim will present promising new data on non-small cell lung cancer as well as head-and-neck cancer for its leading investigational compound BIBW 2992 at the American Society of Clinical Oncology (ASCO) annual meeting in Chicago, June 4-8, 2010.

4 Jun 2010

Caltech biologists pinpoint molecular changes that help allow global spread of resistance to Tamiflu

Biologists at the California Institute of Technology have pinpointed molecular changes that helped allow the global spread of resistance to the antiviral medication Tamiflu (oseltamivir) among strains of the seasonal H1N1 flu virus.

4 Jun 2010

Advanced applications of Nanoflex technology to be presented at New Cardiovascular Horizons Meeting

ULURU Inc. announced today that advanced applications of the Nanoflex technology, related to future products in drug delivery and tissue engineering, will be presented at the 11th annual New Cardiovascular Horizons Meeting to be held in New Orleans, Louisiana on June 2-5, 2010. This meeting is the largest medical meeting that focuses on peripheral artery disease and peripheral interventions, including wound care for vascular ulcers, the application of advanced therapies for limb salvage and amputation prevention.

4 Jun 2010

McMaster University researchers discover chemical clue directing Staphylococcus aureus

McMaster University researchers have discovered a central controller or processing unit of a superbug's weaponry. An article on the breakthrough appears in the high-impact journal Science today.

4 Jun 2010

Phase 1B clinical study with PMX-60056 meets safety and efficacy endpoints: PolyMedix

PolyMedix, Inc., an emerging biotechnology company focused on developing new therapeutic drugs to treat acute cardiovascular disorders and infectious diseases, has successfully completed a second Phase 1B clinical safety and pilot efficacy study with PMX-60056, a small synthetic molecule designed to reverse heparin and low molecular weight heparin anticoagulants.

3 Jun 2010

Discovery reveals a new approach to target cancer

Researchers at the University of Pittsburgh Cancer Institute (UPCI) and the School of Medicine have discovered that inhibiting a key molecule in a DNA repair pathway could provide the means to make cancer cells more sensitive to radiation therapy while protecting healthy cells.

3 Jun 2010

Molecule News and Research

AMG 386 demonstrates antitumor activity in Phase 2 trial involving patients with recurrent ovarian cancer

Exelixis reports updated interim data from trials of XL765 small molecule inhibitor of PI3K and mTOR

Tranzyme Pharma receives BioQuébec's 2010 Genesis Award for "Innovation"

Ipilimumab extends survival of metastatic melanoma patients: Study

Plexxikon announces Phase 1 extension study results of PLX4032 in metastatic colorectal cancer

Positive results from Phase 3 trial of ipilimumab in patients with metastatic melanoma

Endocyte presents interim results from phase II trial of EC145 plus Doxil for platinum-resistant ovarian cancer

Celldex reports interim positive results from rindopepimut Phase 2b study for GBM at ASCO

New clinical research findings on oncology to be highlighted at ASCO 2010

Vandetanib in combination with chemotherapy improves progression-free survival in patients with lung cancer

Ascenta Therapeutics, sanofi-aventis sign global licensing agreement for cancer drug candidates

Ascalon International signs license agreement with CerRx

Preclinical data of dual TLR7 and TLR8 agonist in cancer published

Researchers develop biosensors to monitor concentration of c-di-GMP within single living bacteria cells

Boehringer Ingelheim to present new data on BIBW 2992 for NSCLC and head-and-neck cancer at ASCO 2010

Caltech biologists pinpoint molecular changes that help allow global spread of resistance to Tamiflu

Advanced applications of Nanoflex technology to be presented at New Cardiovascular Horizons Meeting

McMaster University researchers discover chemical clue directing Staphylococcus aureus

Phase 1B clinical study with PMX-60056 meets safety and efficacy endpoints: PolyMedix

Discovery reveals a new approach to target cancer

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News